Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;29(1):85-94.
doi: 10.1007/s00467-013-2605-6. Epub 2013 Sep 26.

C3 nephritic factor associated with C3 glomerulopathy in children

Affiliations

C3 nephritic factor associated with C3 glomerulopathy in children

Camille Nicolas et al. Pediatr Nephrol. 2014 Jan.

Abstract

Background: C3 glomerulopathy (C3G) is characterized by predominant C3 deposits in glomeruli and dysregulation of the alternative pathway of complement. Half of C3G patients have a C3 nephritic factor (C3NeF). C3G incorporated entities with a range of features on microscopy including dense deposit diseases (DDD) and C3 glomerulonephritis (C3GN). The aim of this work was to study children cases of C3G associated with C3NeF.

Methods: We reviewed 18 cases of C3G with a childhood onset associated with C3NeF without identified mutations in CFH, CFI, and MCP genes.

Results: Clinical histories started with recurrent hematuria for seven patients, nephrotic syndrome for four, acute post-infectious glomerulonephritis for three and acute renal failure for four. Twelve patients had a low C3 at first investigation. Kidney biopsy showed ten C3GN and eight DDD. Twenty-three percent of the patients tested presented elevated sC5b9. Seven patients relapsed 3 to 6 years after the onset. At the end of follow-up, two patients were under dialysis, 11 had a persistent proteinuria, five had none; four patients did not follow any treatment. Steroids were first used in 80 % of cases.

Conclusions: C3NeF associated C3G has a heterogeneous presentation and outcome. Anti-proteinuric agents may control the disease during follow-up, even after nephrotic syndrome at the onset. The efficiency of immunosuppressive therapy remains questionable.

PubMed Disclaimer

References

    1. Nephrol Dial Transplant. 2004 Dec;19(12):3160-4 - PubMed
    1. Am J Med. 1983 Feb;74(2):175-92 - PubMed
    1. J Pediatr. 1990 May;116(5):S109-14 - PubMed
    1. Kidney Int. 2006 Feb;69(3):504-11 - PubMed
    1. Clin Microbiol Rev. 2010 Oct;23(4):740-80 - PubMed

Substances

LinkOut - more resources